Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | $2.00M | — | — |
| Operating income | -$31.1M | -$30.7M | -$54.5M | -$56.9M |
| Operating margin | — | -1537.0% | — | — |
| Net income | -$30.5M | -$27.9M | -$45.6M | -$51.0M |
| Net margin | — | -1393.8% | — | — |
| EPS (diluted) | -$165.20 | -$2.66 | -$1.45 | -$1.58 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | -$24.5M | -$23.8M | -$42.4M | -$45.6M |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $158K | $75.1M | $75.8M | $35.0M |
| Total assets | $33.0M | $96.7M | $160M | $116M |
| Total liabilities | $5.36M | $5.65M | — | — |
| Shareholders' equity | -$187M | $91.1M | $156M | $111M |
| Retained earnings | -$222M | -$250M | -$295M | -$346M |
| Shares (wtd avg diluted) | 185K | 10.5M | 31.4M | 32.3M |
Every figure is extracted from Sagimet Biosciences Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.